Report Overview

The global clostridium diagnostics market was valued at US$ 2 billion in 2021 and is expected to witness a CAGR of 12% during the forecast period.

Market Fundamentals 

Clostridium is a gram-positive bacterium belonging to phylum Firmicutes family. Illnesses carried on by Clostridium sortellii, including myonecrosis, peritonitis, arthritis, endocarditis, and pneumonia. C. difficile is the etiological agent causing diarrhoea. This illness's diagnosis is confirmed using various imaging methods, including radiography, CT, and endoscopy. Additionally, throughout the forecast period, the market expansion is anticipated to be aided by evolving lifestyles, expanding healthcare infrastructure, and technology developments like artificial intelligence and automation.

[7683843]

Market Dynamics

Due to the rising incidence of illnesses, medical technology developments, and rising investments in R&D activities, the pharmaceutical and healthcare industries have seen significant changes recently. Growing public and private sector funding, pharmaceutical industry investments, drug discovery advancements, and market revenue growth contribute to this. Additional factors driving market expansion include the availability of cutting-edge technology in both emerging and developed nations, improvements to healthcare infrastructure, and increased consumer acceptance of rapid testing and point-of-care diagnostics. Moreover, it is anticipated that prominent corporations would continue to profit from the persistent demand for various treatments and devices during the prolonged epidemic. The necessity for early diagnosis, rising acceptance of precision medicine, and increasing demand for in-home care drive the market expansion.

Market Ecosystem

The global clostridium diagnostics market has been analysed from four perspectives: type, test, end user and region.

Clostridium Diagnostics Market by Type

[9798743]

Based on type, the global clostridium diagnostics market has been segmented into clostridium difficile, clostridium perfringens, clostridium botulinum, clostridium tetani, and clostridium sordellii. 

The clostridium difficile segment dominated the market during the forecast period due to its substantial percentage, including increased antibiotic use, which raises the risk of contracting this disease.

Clostridium Diagnostics Market by Test

Based on tests, the global clostridium diagnostics market has been segmented into immunoassay and molecular diagnostics. 

The immunoassay segment accounts for the largest revenue share in the global market. Immunoassays are more accurate than conventional cell culture and PCR-based tests. Immunoassay-based testing has a decreased likelihood of false positive or false negative results. Moreover, immunoassays generate findings quickly and are comparatively easy to use. Because of this, they are more appealing to medical professionals than molecular diagnostic techniques. Moreover, immunoassay tests are considerably less expensive than other diagnostic tests, which makes them more affordable and available to a wider range of people. This contributes to further boosting the market for clostridium diagnostic immunoassays.

Clostridium Diagnostics Market by End-user

Based on end-user, the global clostridium diagnostics market has been segmented into hospitals, government diagnostic laboratories, and independent/private laboratories. 

The independent/private labs segment has emerged as the most profitable segment in terms of revenue share. It is expected to expand quickly during the forecast period. The frequent usage of clostridium diagnostics tools in labs and their accessibility have been the high-impact growth drivers, whereas as hospitals increasingly prefer to undertake various tests, including invasive and non-invasive diagnoses, the hospital segment accounted for a sizable revenue share due to their superior diagnostic technologies, hospitals will continue to be preferred by patients in the coming years.

Clostridium Diagnostics Market by Region

Based on region, the global clostridium diagnostics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America is one of the worlds' dominant centres for clostridium diagnostics due to the availability of technologically advanced technologies, significant government financing, substantial spending on cardiac research and development projects, and high patient awareness levels. On the other hand, the Asia Pacific, including India and China, is predicted to have profitable growth during the projected period due to increased healthcare costs and clostridium prevalence in developing countries.

Competitive Landscape

The prominent players in the global clostridium diagnostics market include: 

• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Acurx Pharmaceuticals
• Siemens AG
• Becton, Dickinson and Company
• Beckman Coulter, Inc.
• Cubist Pharmaceuticals
• Sysmex India Pvt. Ltd.
• Thermo Fisher Scientific Inc.
• Avisa Pharma
• Fujirebio US, Inc.
• MGB Bio Pharma
• bioMrieux SA
• Diazyme Laboratories, Inc. 

However, the expanding collaboration among the companies is projected to eliminate the barriers and expand the market. For instance, in March 2021, Ferring Pharmaceutical and the Peggy Lillis Foundation for Clostridium Difficile Infections joined forces through a new sponsorship to support new and old patient advocacy programmes.

Strategic development

• In March 2022, MGB Bio Pharma is a developer of antibiotics for microorganisms with medication resistance. The business includes a pipeline of topical, injectable, oral, and antibacterial compounds. MGB-BP-3, the leading product, can combat various Gram-positive bacteria, such as MRSA, VRE, and Clostridium difficile. These elements are likely to help the sector in the future.
• In August 2021, a novel vaccine developed by Uvepharma Canada Corporation Inc. was demonstrated to protect against necrotic enteritis (NE) caused by Clostridium perfringens Type A in broiler chickens.
• In February 2019, in an agreement for vaccine testing, Merck Animal Health and Rapid Genomics agreed that Merck would exclusively use the company's Viral Flex-Seq instrument.

Frequently Asked Questions About This Report